Clifford, Royce E. http://orcid.org/0000-0002-5515-4336
Maihofer, Adam X.
Chatzinakos, Chris
Coleman, Jonathan R. I. http://orcid.org/0000-0002-6759-0944
Daskalakis, Nikolaos P. http://orcid.org/0000-0003-1660-9112
Gasperi, Marianna
Hogan, Kelleigh
Mikita, Elizabeth A. http://orcid.org/0000-0002-2113-8274
Stein, Murray B. http://orcid.org/0000-0001-9564-2871
Tcheandjieu, Catherine
Telese, Francesca http://orcid.org/0000-0003-3877-0628
Zuo, Yanning
Ryan, Allen F.
Nievergelt, Caroline M. http://orcid.org/0000-0001-5766-8923
Funding for this research was provided by:
U.S. Department of Veterans Affairs (RX004293, BX005920)
Article History
Received: 20 June 2023
Accepted: 4 January 2024
First Online: 19 January 2024
Competing interests
: M.B.S. has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sumitomo Pharma, and Roche/Genentech. M.B.S. has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on <i>Depression and</i> Anxiety (Editor-in-Chief), <i>Biological</i> Psychiatry (Deputy Editor), and <i>UpToDate</i> (Co-Editor-in-Chief for Psychiatry). A.F.R. is a co-founder of and holds stock in Otonomy, Inc. All other authors declare no competing interests.